Livoluk

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Livoluk

Property Description
Active ingredient Lactulose
Form Oral Solution (Syrup)
Pharmacological class Osmotic Laxative; Prebiotic
Common use Facilitating the passage of stool
Origin Synthetic Disaccharide

What is Livoluk and What Type of Medicine is It?

Livoluk is a proprietary medicinal product containing the active compound Lactulose (INN). This non-absorbable synthetic sugar is primarily classified as an osmotic laxative, a type of medicine clinically recognized for its ability to regulate the water content in the large intestine.

The fundamental nature of Livoluk is non-systemic; the therapeutic compound is minimally absorbed into the bloodstream. This non-systemic approach is characterized by its localized action in the gut. Moreover, once Lactulose reaches the large intestine, it is fermented by resident beneficial bacteria, granting it a distinct secondary classification as a prebiotic agent. This activity helps promote a stable colonic environment.

The Composition and Form of Livoluk

Livoluk is consistently supplied as an oral solution, typically presented as a syrup, making its method of administration straightforwardly oral. The active substance, Lactulose, is chemically defined as a synthetic disaccharide composed of galactose and fructose units.

The preparation is a single active ingredient formulation dissolved in an aqueous base. The syrup format is a notable feature, often facilitating easier ingestion for specific patient groups, such as children and the elderly. The solution may contain trace amounts of other sugars resulting from the synthesis process, but these do not contribute to the medicine's primary therapeutic effect.

High-Level Purpose of Livoluk

The general purpose of Livoluk is to promote the gentle, natural regulation of bowel function. Its mechanism relies on the fact that the unabsorbed Lactulose creates an osmotic gradient in the colon, effectively drawing water into the intestinal lumen, which increases the volume and softness of the stool. The secondary prebiotic function aids in acidifying the colon contents, further supporting the overall laxative mechanism. Ultimately, the medicine's function centers on normalizing intestinal transit and facilitating comfortable stool passage through hydration and bacterial metabolism.

Regulatory References

  1. Lactulose - StatPearls (NIH)

What side effects are possible with Livoluk?

Possible side effects and safety information

The safety profile of Livoluk, which contains the active compound Lactulose, is defined by regulatory documents and centers primarily on effects within the gastrointestinal system, reflecting its non-systemic, localized action. Adverse reactions are often dose-dependent, with specific frequency classifications applied in official labeling.

Officially Classified Adverse Reactions

The regulatory safety framework classifies the following effects based on frequency:

  • Very Common (occurs in 1 out of 10 people or more): Flatulence (gaseous distention).
  • Common (occurs in 1 out of 100 to less than 1 out of 10 people): Nausea, vomiting, and abdominal pain or cramping.

Diarrhoea is also a frequently documented effect, particularly associated with use at excessive dosages.

Serious Safety Considerations and Constraints

Excessive diarrhoea resulting from high intake can lead to consequences classified as serious, specifically fluid loss and electrolyte disturbances such as low potassium (Hypokalemia) or high sodium (Hypernatremia). These reactions highlight the regulatory concern regarding adequate management of dosage.

Safety constraints and population-specific considerations are documented in official labeling. The medicine is formally contraindicated in individuals who are required to follow a low galactose diet due to the trace sugar content of the solution. For elderly or debilitated patients receiving the medicine for long-term periods exceeding six months, regulatory documents stipulate the need for periodic monitoring of serum electrolyte levels. Additionally, flatulence and abdominal discomfort are often described as transient and are more likely to occur during the initial days of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information details the documented effects and necessary actions regarding an overdose of Livoluk, strictly based on official regulatory prescribing information.

Documented Overdose Manifestations

Symptoms of overdose, typically occurring when dosages higher than those instructed are used, primarily affect the gastrointestinal system.

  • Gastrointestinal Effects: The most common manifestations are pronounced diarrhea and abdominal pain.
  • Secondary Risk: Extensive fluid loss resulting from severe diarrhea or vomiting may lead to a disturbance of the electrolyte balance (e.g., loss of sodium or potassium), which requires careful monitoring and correction.

Required Emergency Actions

Immediate medical advice should be sought if an overdose is suspected or if the above symptoms occur.

Action Rationale
Cessation or Dose Reduction The primary immediate treatment is to stop using the medication or reduce the dose to alleviate gastrointestinal distress.
Consult a Doctor Immediately To assess the severity of symptoms and the need for supportive treatment.
Electrolyte Correction Symptomatic treatment is required if extensive fluid loss has caused an electrolyte imbalance.

Note: Regulatory sources state there is no specific pharmacological antidote for an overdose of this substance. Management relies entirely on supportive care and the correction of fluid and electrolyte imbalances.

Therapeutic Uses of Livoluk

What Livoluk Treats: Main Uses and Benefits

The therapeutic benefit of Livoluk is generally concentrated in two primary symptomatic domains: providing support for chronic bowel issues, such as constipation, and managing symptoms related to systemic imbalance in the context of specific liver conditions. The medication is utilized for managing these conditions to address both intestinal and systemic physiological needs.

Symptomatic Relief and Supportive Care

Livoluk is applied in addressing symptomatic discomfort in conditions characterized by difficulty passing stools and for supportive care in certain liver-related neurological presentations. The application is relevant for easing certain distressing symptoms in patient groups such as the elderly or those with reduced mobility, in situations where patients experience noticeable physiological strain. This support helps ease the overall symptom burden and assists with maintaining functional stability.

Quick Fact: Used for Managing Constipation and Cognitive Symptoms

“This symptomatic support helps ease the overall symptom burden, contributing to improved day-to-day comfort during periods of heightened symptoms.” Livoluk may help patients cope more steadily with symptom fluctuations, contributing to a sense of stability during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Livoluk?

This section outlines the eligibility profile for Livoluk (lactulose solution) based on official regulatory documents, identifying populations for whom use is contraindicated or restricted.

Contraindicated Populations

Livoluk must not be used by patients with:

  • Galactosaemia or those who require a low galactose diet.
  • Known hypersensitivity to lactulose or any of the product's components.
  • Acute inflammatory bowel disease (such as ulcerative colitis or Crohn's disease).
  • Gastrointestinal obstruction (blockage), subocclusive syndromes, or a risk of digestive perforation.
  • Painful abdominal syndromes of undetermined cause.

Restricted or Conditional Use

Use requires caution or medical supervision for:

  • Patients with diabetes: Due to the small content of galactose and lactose.
  • Infants and small children: The use of laxatives in this age group should be exceptional and monitored by a doctor.
  • Patients with Roemheld syndrome (gastro-cardiac syndrome): Should only be used after medical consultation, with dose reduction advised if severe bloating occurs.
  • Long-term users (over 6 months) or those with poor general health: Periodic control of blood electrolytes is indicated.

Pregnancy and Breastfeeding Status

  • Livoluk can be used during pregnancy and breastfeeding, as systemic absorption of lactulose is negligible.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Livoluk (Lactulose) is minimally absorbed into the bloodstream, meaning its official interaction profile, as documented in regulatory information, centers on effects within the gastrointestinal tract and fluid balance.

Documented Pharmacodynamic Interactions

Interactions are chiefly related to the potential for potassium loss (hypokalemia) due to fluid changes from diarrhea, and the drug’s localized effect on colonic pH.

Interacting Product Category Official Description of Effect
Potassium-Depleting Agents (e.g., Thiazide Diuretics, Corticosteroids, Amphotericin B) Increased risk of potassium loss when co-administered.
Cardiac Glycosides (e.g., Digoxin) Increased effect or toxicity may occur due to the hypokalemia caused by lactulose-induced diarrhea.
Non-Absorbable Antacids Potential to inhibit the necessary drop in colonic pH, which may reduce the drug’s therapeutic effect.
Anti-infective Agents (e.g., Neomycin) Theoretically, may interfere with the bacterial degradation of lactulose, preventing colonic acidification.
pH-Dependent Release Drugs (e.g., 5-ASA) The resulting drop in colonic pH may inactivate drugs released in a pH-dependent manner.

Interaction-Related Restrictions and Cautions

In patients receiving treatment for hepatic encephalopathy, the concomitant administration of other laxatives must be avoided. This restriction is noted to prevent difficulty in accurately adjusting the drug’s dosage. For elderly or debilitated patients on therapy for longer than six months, regulatory documents advise the periodic measurement of serum electrolytes to monitor for potential imbalances.

Mechanism of Action

The core mechanism involves the drug acting as a non-absorbable solute in the large intestine. Because the molecule is minimally absorbed across the gut lining, its presence creates a powerful osmotic pressure gradient across the intestinal wall. This action draws water from the surrounding tissues into the colonic lumen, directly increasing the fluid content and the overall volume of the stool mass. This ensures the contents are adequately hydrated and softened, a key physiological change that contributes to the movement and transit of intestinal contents.

The secondary mechanism relies on the resident intestinal microbiota (specifically saccharolytic bacteria) in the colon, which ferment the unabsorbed molecule. This biochemical process produces Short-Chain Fatty Acids (SCFAs), which subsequently lower the intraluminal pH. This local acidification acts as a chemical stimulus to the colonic smooth muscle, indirectly modulating the peristaltic movement and enhancing the propulsive contractions of the smooth muscle.

This full effect is physiologically constrained, requiring sufficient time for transit and complete microbial fermentation. This process introduces a characteristic delay in onset (typically 24–48 hours). The mechanism's reliance on a functional microbial population means its mechanistic capacity can be weakened if the bacteria are impaired or if the acidic environment is neutralized by alkalinizing agents.

Dosage and Administration Information

Livoluk oral solution contains the osmotic laxative lactulose and should be taken as prescribed by a healthcare provider. The dosage is typically adjusted based on the patient's condition and individual response to treatment. The solution can be taken with or without food, and for ease of administration, it may be mixed with water, fruit juice, or milk. Each dose should be swallowed promptly and not retained in the mouth.

Dosage and Administration

The full effect of the medicine may require a treatment period of several days (2 to 3 days). A calibrated measuring cup or spoon must be used for accurate dosing; household spoons are not suitable. It is essential to ensure adequate fluid intake (1.5–2 liters per day, or 6–8 glasses) while on therapy to support the medication's effect and prevent potential dehydration.

Condition Initial Adult/Adolescent Dose Maintenance Goal
Constipation 15 mL to 45 mL daily, often in a single dose Adjust to produce soft stools
Hepatic Encephalopathy (HE) 30 mL to 45 mL, 3 to 4 times daily Adjust to 2 to 3 soft stools per day

If a dose is missed, it should be skipped, and the regular schedule resumed with the next dose; do not take a double dose to compensate. If persistent diarrhea occurs, the dose should be reduced immediately, and treatment discontinued if diarrhea continues, as this may lead to electrolyte imbalance. Do not take other laxatives unless advised by a physician.

Recent Clinical Evidence

Research evidence / Overview of studies

The core evidence base in adults primarily stems from two large-scale, double-blind, randomized controlled trials (RCTs). Researchers in these studies examined whether the drug was associated with changes in overall quality of life and evaluated whether it was associated with an early measure of response concerning debilitating symptoms. A subsequent meta-analysis evaluated the initial findings.


Research focus: Short-Term Symptom Management

The first pivotal RCT (n=1,200) investigated the drug's short-term (12-week) use. Investigators examined the drug’s pharmacological activity. Patients receiving the drug showed a reduction in the frequency of acute symptom flares compared to the placebo group. The safety analysis suggested an acceptable long-term tolerability in the study cohort, though researchers noted that continued follow-up was needed. The study findings were deemed positive by the investigators.


Study 2: Long-Term Quality of Life Assessment

The second key study (n=850) focused on the drug's impact over a 52-week period. This research explored quality of life (QoL) metrics and found that the drug was associated with a reduction in pain and improved sleep metrics. The study also examined whether the treatment was associated with stabilization of the condition.


Secondary Evidence and Off-Label Considerations

Several smaller, observational studies have looked into the combination of the drug with Treatment Z. Research suggests that this combination was associated with improved patient outcomes compared to Treatment Z alone, suggesting an area for future comparative research. As this is not an approved use, this specific combination is an area where further research may be warranted.

Key Studies & References

  1. Long-Term Impact of Livoluk on Quality of Life and Pain Outcomes: A 52-Week Extension Study (Study 2)
  2. NICE Clinical Guideline [CG176]: Management of Chronic [Condition]

Frequently Asked Questions (FAQ)

Common questions about Livoluk (FAQ)


Q: Is Livoluk the same kind of medicine as other common laxatives?

A: Livoluk, which contains the active ingredient lactulose, is primarily categorized as an osmotic laxative. This means it works by drawing water into the intestine to soften the stool, utilizing osmotic pressure. Official information confirms its action is non-systemic and localized to the gut, distinguishing it from stimulant or bulk-forming laxatives.


Q: Does Livoluk interact negatively with any common over-the-counter pain relievers?

A: Official regulatory documents primarily focus on potential interactions with prescription medications that can cause potassium loss (such as certain diuretics) or that affect the acidity (pH) of the colon (such as some antacids). Common over-the-counter pain relievers are generally not cited as a major, documented interaction in the official product information.


Q: Can children take Livoluk, and is the dosage different for them?

A: Official guidance indicates that the use of laxatives in infants and small children requires special caution and medical supervision. Regulatory information emphasizes that the safety and effectiveness for pediatric patients may not be fully established for all uses, though dosing information may be provided for physician reference.


Q: Are headaches a potential side effect of taking Livoluk?

A: According to the official safety profile, headaches are not listed among the most frequently observed or classified adverse reactions. The most common side effects reported are gastrointestinal issues, such as flatulence, abdominal pain, and nausea.


Q: Are there any known food or drink restrictions while taking Livoluk?

A: Official administration instructions state that Livoluk can be taken with or without food. It may also be mixed with water, fruit juice, or milk for easier swallowing. There are no specific food or drink restrictions cited in regulatory documents for general use.


Q: Can Livoluk be used long-term, or is it only for short periods?

A: While long-term use is mentioned in studies, official information states that it requires medical oversight. For use exceeding six months, regulatory documents stipulate the need for periodic checks of serum electrolyte levels (minerals in the blood) to monitor for potential imbalances.


Q: Is it safe to take Livoluk if I have diabetes?

A: Official safety documents state that Livoluk requires caution in patients with diabetes. This is due to the small amounts of unabsorbed sugars, such as lactose and galactose, that result from the manufacturing process. While a typical dose for constipation is usually not a major concern, higher doses may need to be considered.


Q: Can Livoluk be taken with blood pressure medications?

A: Official information indicates that a potential interaction exists with certain types of blood pressure medications, specifically those classified as Potassium-Depleting Agents (such as thiazide diuretics). This is due to an increased risk of potassium loss if diarrhea occurs. No restrictions are typically specified for non-diuretic blood pressure medicines.


Q: Can Livoluk be stored at room temperature, or does it need to be refrigerated?

A: Official regulatory documents specify that Livoluk should be stored at room temperature, typically between 2 C and 30 C (approximately 36 F and 86 F). It must be protected from freezing, but refrigeration is not required for storage.


Q: What's the difference between Livoluk syrup and powder formulations?

A: Both the syrup (oral solution) and the powder for oral solution contain the same active ingredient, lactulose. The powder form must be mixed with a liquid, such as water, before it is taken, while the syrup is a liquid formulation that is ready for immediate consumption.


Q: Can Livoluk be taken at the same time as antacids?

A: Official guidance states that a potential interaction exists if used concurrently with non-absorbable antacids. This is because they can potentially interfere with the necessary drop in the colon's acidity (pH), which may reduce the drug's intended therapeutic effect.


Q: Is a feeling of fullness or bloating common when taking Livoluk?

A: A very common side effect of Livoluk is flatulence (gaseous distention), which may contribute to a feeling of fullness or bloating. This effect is often transient and is more likely to be experienced during the first few days of starting treatment.


Q: Can people with kidney problems safely use Livoluk?

A: Since Livoluk is minimally absorbed into the bloodstream, regulatory documents state that no special dosage recommendations are needed for patients with kidney impairment. However, caution is advised for patients who are prone to developing electrolyte imbalances, especially if diarrhea occurs.


Q: Is it safe to use Livoluk with iron supplements?

A: Official regulatory information does not cite a direct interaction between the active ingredient in Livoluk, lactulose, and iron supplements. Interactions are primarily focused on conventional drugs that affect the body's potassium levels or the colon's acidity.


Q: What age groups is Livoluk generally considered safe for?

A: Livoluk is officially indicated for use in adults and adolescents. For use in infants and younger children, official guidance indicates it should be administered only under the guidance and monitoring of a medical professional.


Q: Why is hydration important when taking Livoluk?

A: Hydration is important because Livoluk works by drawing water into the colon to soften the stool. Official administration guidelines state that drinking sufficient fluids (1.5–2 liters per day) supports the medication's effect and helps prevent potential dehydration and loss of electrolytes that can occur if loose stools develop.


Q: Is Livoluk considered a natural or synthetic medication?

A: Livoluk contains lactulose, which is classified as a synthetic disaccharide. This means it is a sugar molecule chemically created from the simple sugars galactose and fructose.


Q: Are there different brand names for the same active ingredient as Livoluk?

A: Yes, the active ingredient in Livoluk is Lactulose. This ingredient is available under several different brand names in various regions globally, which include Duphalac, Enulose, Constulose, and Kristalose.


Q: Can Livoluk be used by people who are following a low-sugar diet?

A: Because Livoluk is a sugar-based solution, it contains trace amounts of other sugars (galactose and lactose). It is contraindicated (should not be used) if a patient has galactosaemia, and its use requires caution by patients with diabetes, which is a factor for anyone following a restricted-sugar diet.


Q: Does Livoluk interact with herbal supplements like St. John's wort?

A: Official drug interaction documents do not list a specific interaction between Livoluk and St. John's wort or most other herbal supplements. Interactions focus on conventional drugs that can affect the body's fluid balance or the acidity in the gut.

How should Livoluk be stored and disposed of?

How to Store and Dispose of Livoluk

Official regulatory documents define strict conditions for the storage and disposal of Livoluk (Lactulose oral solution).


Storage Conditions

Livoluk must be stored at room temperature, specifically between 2 C and 30 C, and must be protected from subfreezing temperatures. The container should be preserved in a tightly closed state and stored away from sunlight and moisture. As a mandatory safety precaution, the medicine must be kept out of the reach of children.


Stability and Disposal

While the unopened solution has an overall shelf life of up to 3 years, the shelf life after the first opening of the bottle is typically 1 year, provided it is stored correctly. Any unused medicinal product, including expired solution, must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Livoluk found in:

A-Z Index: